Language:

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.367-385 [Peer Reviewed Journal]

The Alzheimer's Association ;2011 The Alzheimer's Association ;Copyright © 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. ;ISSN: 1552-5260 ;EISSN: 1552-5279 ;DOI: 10.1016/j.jalz.2011.05.2351 ;PMID: 21784348

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
Author: Sperling, Reisa A ; Jack, Clifford R ; Black, Sandra E ; Frosch, Matthew P ; Greenberg, Steven M ; Hyman, Bradley T ; Scheltens, Philip ; Carrillo, Maria C ; Thies, William ; Bednar, Martin M ; Black, Ronald S ; Brashear, H. Robert ; Grundman, Michael ; Siemers, Eric R ; Feldman, Howard H ; Schindler, Rachel J
Subjects: Alzheimer Disease - complications ; Alzheimer Disease - pathology ; Alzheimer Disease - therapy ; Alzheimer's disease ; Amyloid ; Amyloid - immunology ; Amyloid - metabolism ; Animals ; Brain Edema - etiology ; Brain Edema - metabolism ; Brain Edema - pathology ; Cerebral Hemorrhage - etiology ; Cerebral Hemorrhage - metabolism ; Cerebral Hemorrhage - pathology ; Clinical guidelines ; Clinical trials ; Clinical Trials as Topic - methods ; Clinical Trials as Topic - standards ; Disease Models, Animal ; Humans ; Imaging ; Magnetic Resonance Imaging ; Microhemorrhage ; MRI ; Neurology ; Pathology ; Signals ; Societies, Medical - organization & administration ; Therapeutic trials ; Vasogenic edema
Is Part Of: Alzheimer's & dementia, 2011-07, Vol.7 (4), p.367-385
Description: Abstract Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in Alzheimer’s disease (AD). In response to concerns raised by the Food and Drug Administration, the Alzheimer’s Association Research Roundtable convened a working group to review the publicly available trial data, attempts at developing animal models, and the literature on the natural history and pathology of related conditions. The spectrum of ARIA includes signal hyperintensities on fluid attenuation inversion recoverysequences thought to represent “vasogenic edema” and/or sulcal effusion (ARIA-E), as well as signal hypointensities on GRE/T2∗ thought to represent hemosiderin deposits (ARIA-H), including microhemorrhage and superficial siderosis. The etiology of ARIA remains unclear but the prevailing data support vascular amyloid as a common pathophysiological mechanism leading to increased vascular permeability. The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing AD clinical trials, as well as directions for future research.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 1552-5260
EISSN: 1552-5279
DOI: 10.1016/j.jalz.2011.05.2351
PMID: 21784348
Source: MEDLINE

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

The Alzheimer's Association ;2011 The Alzheimer's Association ;Copyright © 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. ;ISSN: 1552-5260 ;EISSN: 1552-5279 ;DOI: 10.1016/j.jalz.2011.05.2351 ;PMID: 21784348

Searching Remote Databases, Please Wait